Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

NCT02669017 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

183

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma
Burkitt's Lymphoma
Chronic Lymphocytic Leukemia
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Follicular
Lymphoma, Mantle-Cell
Lymphoma, Marginal Zone
Waldenstrom Macroglobulinemia
Primary Mediastinal B-cell Lymphoma

Interventions

DRUG: ADCT-402

Sponsor

ADC Therapeutics S.A.